Pharmaceutical group · United States
Biogen
A group of 16 companies with 117 medicines in 9 countries.
Group structure
16 companies in 11 countries
Canada1
Latvia1
Lithuania1
Netherlands1
6 more countries
Romania1
Singapore1
Spain1
United Kingdom1
United States1
Headquarters not stated4
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Medicines
Every medicine of every company in the group, current ones first.
1–25 of 117
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ADUHELM170mg/1.7ml (100mg/ml) | 300mg/3ml (100mg/ml) · Injectable | Aducanumab | United States | Marketed | 2021 |
| AVONEX30 mcg / 0.5 ml · Solution | Interferon beta-1a | Canada | Marketed | 2005 |
| Avonex | Betainterferona | Brazil | Authorised | 2008 |
| AVONEX60 mcg / ml · Powder For Solution | Interferon beta-1a | Canada | Authorised | |
| Avonex30mcg/0.5ml · Injection | Interferon beta-1a | United States | Marketed | 2012 |
| Avonex | Interferon beta-1a | EU (EMA) | Authorised | 1997 |
| AVONEXSoluzione iniettabile | Interferon beta-1a | Italy | Authorised | |
| AVONEX1a 30ug/ml · Vial | Interferon beta-1a | United States | Marketed | 1996 |
| Avonex30mcg/0.5ml · Injection | Interferon beta-1a | United States | Marketed | 2003 |
| AVONEX 30 microgram/0,5 ml, oplossing voor injectieOplossing voor injectie | Interferon beta-1a | Netherlands | Authorised | 1997 |
| AVONEX 30 microgram/0,5 ml oplossing voor injectie, in voorgevulde penOplossing voor injectie | Interferon beta-1a | Netherlands | Authorised | 2011 |
| AVONEX 30 microgramos/0,5 ml SOLUCION INYECTABLE0,3 µg · Solución inyectable en jeringa precargada | Interferon beta-1a | Spain | Authorised | 2004 |
| AVONEX 30 microgramos/0,5 ml SOLUCION INYECTABLE EN PLUMA PRECARGADA30 µg · Solución inyectable en pluma precargada | Interferon beta-1a | Spain | Marketed | 2011 |
| PLEGRIDYSoluzione iniettabile in siringa pre-riempita | Peginterferon beta-1a | Italy | Authorised | |
| PLEGRIDY63 mcg / 0.5 ml · Liquid | Peginterferon beta-1a | Canada | Authorised | |
| PLEGRIDY63 mcg / 0.5 ml + 94 mcg / 0.5 ml · Kit, Liquid | Peginterferon beta-1a | Canada | Marketed | 2015 |
| Plegridy94mcg/0.5ml · Injection | Peginterferon beta-1a | United States | Marketed | 2014 |
| Plegridy94mcg/0.5ml · Injection | Peginterferon beta-1a | United States | Marketed | 2014 |
| PLEGRIDY1a 125micrograms/0.5ml · Injectable | Peginterferon beta-1a | United States | Marketed | 2014 |
| Plegridy63mcg/0.5ml · Injection | Peginterferon beta-1a | United States | Marketed | 2014 |
| PLEGRIDY125 mcg / 0.5 ml · Liquid | Peginterferon beta-1a | Canada | Marketed | 2015 |
| Plegridy125mcg/0.5ml · Injection | Peginterferon beta-1a | United States | Marketed | 2014 |
| Plegridy | Peginterferon beta-1a | EU (EMA) | Authorised | 2014 |
| PLEGRIDY94 mcg / 0.5 ml · Liquid | Peginterferon beta-1a | Canada | Authorised | |
| Plegridy63mcg/0.5ml · Injection | Peginterferon beta-1a | United States | Marketed | 2014 |
Countries
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 20 | 19 | 1 | CompaniesAll medicines |
| Netherlands | 19 | 19 | 0 | CompaniesAll medicines |
| Canada | 18 | 15 | 3 | CompaniesAll medicines |
| Spain | 17 | 17 | 0 | CompaniesAll medicines |
| European Union (EMA) | 11 | 9 | 2 | CompaniesAll medicines |
| Romania | 11 | 0 | 11 | CompaniesAll medicines |
| Brazil | 9 | 5 | 4 | CompaniesAll medicines |
| Italy | 9 | 9 | 0 | CompaniesAll medicines |
| Saudi Arabia | 3 | 3 | 0 | CompaniesAll medicines |
Also in the registers of France, Serbia, United Kingdom
Therapeutic areas
The ATC groups most of its medicines belong to, largest first.
- ImmunosuppressantsAntineoplastic and immunomodulating agents · ATC L04A
- ImmunostimulantsAntineoplastic and immunomodulating agents · ATC L03A
- Other drugs for disorders of the musculo-skeletal systemMusculo-skeletal system · ATC M09A
- Other nervous system drugsNervous system · ATC N07X
- PsychoanalepticsNervous system · ATC N06A
Top substances
The active substances in most of its medicines.
- Peginterferon beta-1a23 medicines
- Interferon beta-1a16 medicines
- Dimethyl12 medicines
- Natalizumab12 medicines
- Nusinersen12 medicines
- Zuranolone9 medicines
- Omaveloxolone7 medicines
- Tofersen6 medicines
- Daclizumab5 medicines
- Diroximel fumarate5 medicines
- Fampridine3 medicines
- Aducanumab2 medicines
- Alfaefmoroctocogue1 medicine
- Alfaeftrenonacogue1 medicine
- Betainterferona1 medicine
- Betapeginterferona1 medicine
- Tocilizumab1 medicine
- Water1 medicine
Names in the registers
How the registers spell it, normalised: legal forms, accents and capitals removed.
- biogen brasil produtos
- biogen canada
- biogen idec
- biogen idec denmark manufacturing
- biogen idec ltd innovation house
- biogen international
- biogen latvia
- biogen lithuania
- biogen ma
- biogen netherlands
- biogen singapore
- biogen spain
- biogen u s
Sources and licences
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
ANVISA / CMED, consumer price table; embedded source date 2026-07-21 and retrieval date
Licence: Other (Public Domain)
Anvisa published factual open-data CSV https://dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/TA_CONSULTA_MEDICAMENTOS.CSV, HTTP version Mon, 12 Oct 2026 11:45:25 GMT; acquired 12 October 2026; original source states and timestamps retained.
Licence: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
All 23 sources
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from ACRA Information on Corporate Entities, accessed on 8 October 2026 through Data.gov.sg, under Singapore Open Data Licence version 1.0: https://data.gov.sg/open-data-licence. Structured selection and normalisation by Prognia; original UEN, field and retrieval date retained.
Licence: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
At a glance
- Type
- Pharmaceutical group
- Headquarters
- United States
- Companies
- 16
- Medicines
- 117
- Countries
- 9
Identifiers
- Wikidata
- Q864338